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1. Introduction 
Intravenous heparin remains main stem therapy during cardiac and vascular surgical 
procedures. Heparin therapy is often continued after surgery as part of prophylactic 
treatment (deep venous thrombosis) or bridging therapy (for atrial fibrillation, prosthetic 
valve(s) or Dacron grafts implanted in the heart) until INR levels reach therapeutic levels 
with warfarin therapy.  
Complications resulting from the use of heparin are relatively rare. Among the most 
common are bleeding initiated by excessive inhibition of thrombin and other clotting factors 
and thrombosis caused by inadequate anticoagulation. Heparin Induced Thrombocytopenia 
(HIT) is a rare but potentially life-threatening complication. The literature, which is 
describing HIT is still somewhat confusing since it uses a variety for terms for HIT. Type I 
HIT, sometimes called non-immune heparin-associated thrombocytopenia, is a benign 
process and presents as a mild thrombocytopenia with the platelet count rarely decreasing 
below 100.000/ml. Type I HIT develops early after heparin exposure, typically within 2-3 
days. It probably results from a direct effect of heparin on platelets and occurs in about 
10%–30% of patients receiving heparin (1). 
In contrast, and of greater clinical concern, is type II HIT - and immune mediated syndrome 
associated with platelet activation, increased thrombin production and thrombogenesis 
leading to thrombo-embolic complications.  
The following chapter will briefly discuss the epidemiology, pathogenesis and management 
options for ICU and cardiac surgical patients diagnosed with true HIT.  
2. Epidemiology and pathogenesis 
HIT is a rare complication of heparin therapy primarily affecting the surgical population. It 
occurs in 1-2% of cardiovascular surgery patients, 3%-10% of orthopaedic surgery patients 
and in less than 1% of obstetrical patients. It is higher in the orthopaedic population since 
they usually require prolonged treatment with heparin for DVT prophylaxis following 
surgery. Within the cardiac surgical population, patients who require implantation of a left 
ventricular assist device are at very high risk of developing HIT (> 10%). The incidence of 
HIT in patients treated in medical wards is usually very low (< 0.25%).  
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HIT develops primarily in patients treated with unfractionated heparin (UFH) but it can also 
develop in patients treated with low molecular weight heparins (LMWH) however the 
probability is significantly lower. The classical presentation of HIT might be confusing since 
the thrombocytopenia is usually not severe (a drop of 50-60% when compared to pre-op 
values) and the dominating clinical symptoms are usually related to thrombo-embolic 
complications. The final diagnosis can be confirmed only by additional, relatively 
complicated laboratory tests, which usually take several days to complete. In the meantime, 
if HIT is suspected, treatment should be initiated based on strong clinical indications.  
HIT is an immune reaction associated with the formation of antibodies directed against 
heparin-Platelet Factor 4 (PF-4) complexes. Once heparin is administered to a patient, platelets 
release PF-4, which binds heparin. The heparin-PF-4 complex is highly immunogenic and 
initiates formation of antibodies, which belong to many subgroups (IgG, IgM and IgA). 
Among these classes of immunoglobulins, only IgG is capable of triggering the reaction 
responsible for HIT. The immune system of the patient develops sensitivity (memory) to 
complexes of heparin-PF-4. When a second dose of heparin is given (even a small amount) it 
causes platelet degranulation and release of PF-4. Antibodies then bind to the complexes (Fab 
fragment) and to the surface of platelets (Fc fragment) initiating a cascade of events that result 
in further platelet activation and release of large amounts of PF-4 along with further platelet 
aggregation and thrombin generation. Strong activation of thrombin leads to clot formation 
and subsequent thrombo-embolic events. PF-4 can also bind to other substances, which are 
chemicaly similar to heparin. They belong to a group of molecules called glycosaminoglycans 
(GAGs). Many GAGs are present on the surface of the endothelial cells. This interaction 
amplifies the reaction leading to further platelet activation and aggregation, inflammation and 
propagates clot formation. The above described sequence of events presents clinically as 
thrombocytopenia accompanied by thrombotic complications. 80% of embolic events take 
place in the venous system while the remaining 20% occur in the arterial system. Rarely, HIT 
presents as a systemic reaction, for example disseminated intravascular coagulation (DIC). 
Therefore, HIT should be considered as a pro-thrombotic disorder leading to venous or major 
arterial thrombosis with potentially life-threatening consequences. 
Antibodies against heparin-PF-4 are usually detectable for up to 3 months after the last 
heparin exposure. After the antibodies disappear the patient can be safely treated with 
heparin again. 
3. Diagnosis 
Usually the first clinical suspicion of HIT occurs when the platelet count drops in a patient 
being treated with heparin. Thrombocytopenia is usually not severe (40-60,000) or more 
than 50% of baseline value and it very rarely reaches a level that would cause spontaneous 
bleeding. The incidence of thrombocytopenia usually has a predictable time pattern. There 
are 3 possible clinical scenarios. 
1. Thrombocytopenia occurring 5-10 days after initiating therapy with heparin. This is the 
most common clinical scenario. 
2. Thrombocytopenia occurring within 24 h after initiating heparin therapy (so-called 
acute or rapid-onset HIT). This scenario usually occurs in patients who received 
heparin before surgery, for example as a treatment of unstable angina 
3. Thrombocytopenia with delayed onset. In this scenario the platelet drop occurs many 
days after discontinuing the heparin therapy, usually after the patient is being 
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discharged from hospital. There are some cases of super-acute HIT, which occurs 
almost immediately after a second dose of heparin and presents in the form  systemic 
syndrome with dramatic picture of disseminated intravascular coagulation (DIC). 
Among patients who develop thrombocytopenia caused by HIT, 30-50 % have thrombotic 
complications (Table 1). For many clinicians this is a paradoxical phenomenon since heparin 
is supposed to prevent thrombosis. Venous thrombosis commonly occurs in the lower 
extremities frequently leading to pulmonary embolism (PE) or venous gangrene with distal 
necrosis of the limb.  
 
 
Vasculature Venous Arterial 
Lower extremities DVT Ischemia 
Upper extremities Often with venous catheters  
Adrenal veins Adrenal insufficiency  
Mesenteric or portal Liver dysfunction Bowel or renal 
Cerebral venous sinus Neurological impairment Stroke 
Coronary artery/graft  Ischemia or MI 
Table 1. Thrombosis occurring in HIT. 
HIT may also present as a systemic reaction. With the injection of the second dose of heparin 
(i.e. subcutaneous heparin used for DVT prophylaxis), the patient can develop several 
systemic symptoms, for example skin necrosis, seizures, shivering, hypo- or hypertension 
and tachycardia, or an anaphylactic reaction. As mentioned before the most severe form of 
HIT with systemic presentation is DIC. These symptoms are most likely related to a massive 
release of platelet contents including PF-4 but also histamine, serotonin and other vasoactive 
substances. Additionally, it has been suggested that systemic presentation of HIT includes 
extensive endothelial involvement (PF4 binds to GAGs). Various skin lesions at injection 
sites (erythema induratum, localized or diffuse urticaria, diffuse exanthema) can be also 
suggestive of HIT in 20% of cases. Livedo reticularis is observed in some patients and is 
associated with microangiopathy and microvascular thrombosis of the dermis. Lesions are 
painful, spread centrifugally, and may appear like necrotic purpura with a hemorrhagic 
bullous course, and central necrosis. 75% of patients showing cutaneous symptoms do not 
have any notable thrombocytopenia. 
Basic laboratory tests reveal thrombocytopenia, and sometimes the blood film can show 
fragmentation of destroyed erythrocytes. Severe thrombocytopenia (< 20,000) usually indicates 
that diagnosis of HIT is unlikely. At the same time we need to rule out the most common 
causes of thrombocytopenia in patients being treated in the ICU (massive blood loss, sepsis, 
other drug-induced thrombocytopenia, i.e. vancomycin,). Among other less common 
syndromes causing thrombocytopenia, which should be included in differential diagnosis are: 
antiphospholipid syndrome, disseminated  intravascular coagulation caused by other 
precipitating factor, thrombotic thrombocytopenic purpura and post-transfusion purpura. 
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One of the most popular schemes of assessment and clinical diagnosis of HIT was 
developed by Warkentin and called ‘four T’ (Table 2). T stands for thrombocytopenia, 
timing, thrombosis and other causes. For each category the patient receives 0, 1 or 2 points. 
For a score of 0-3 points, the diagnosis of HIT is unlikely, 4-5 points requires laboratory 
testing to confirm the diagnosis but in most cases does not require treatment, however, if 
patients receive a score of ≥ 6 points treatment should be initiated immediately.  
 
 
Criteria 2 points 1 point 0 points 
Timing  
(of thrombo-
cytopenia) 
5-10 days after 
heparin  or during 1st  
day of therapy if 
heparin within 
previous 30 days 
> 10 days after 
heparin or during 1st 
days of therapy if 
heparin used before 
(31-100 days) 
No previous use of 
heparin 
Thrombocytopenia 
(Platelet count) 
< 50% of baseline 
value or > 20,000 
30-50% of baseline 
value or 10-20,000 
< 30% of baseline 
value or < 10,000 
Thrombosis New incident of 
thrombosis or skin 
necrosis in injection 
site or systemic 
reaction during 
dosing of heparin 
Progressing or 
recurrent thrombosis 
or suspicion of 
thrombosis without 
proven diagnosis 
No thrombo-embolic 
complications 
Other explanations of 
thrombocytopenia 
No other causes Potential causes Confirmed other 
causes 
≥ 6 points mandates initiation of HIT therapy prior to receiving laboratory results 
confirming the diagnosis. 
Table 2. Table describes scoring system used for clinical diagnosis of HIT. 
As mentioned before HIT can be only confirmed by a specific laboratory tests. First, a 
screening test is performed to detect HIT antibodies. This screening test detects all classes of 
immunoglobulins but as mentioned earlier, only IgG can trigger HIT. For example, in the 
case of cardiac surgical patients 20-40% of them develop antibodies, but only 1-2% are truly 
HIT-positive. On the other hand, if the screening test does not detect any immunoglobulins 
the presence of HIT can be ruled out. In the case of a positive HIT screen we need further 
confirmation to be able to show that these (detected) antibodies can trigger platelet 
activation. The most popular assay used is the Serotonin Release Assay (SRA), which uses 
plasma obtained from the patient, heparin and specially prepared, radio-labeled platelets. If 
the patient’s plasma activates platelets (ie: causes release of serotonin) the patient can be 
diagnosed as having HIT (positive). Unfortunately, SRA is performed in only a few centers 
and thus the results of the test are usually not available for several days. An alternative to 
the SRA performed by some laboratories is the heparin-induced platelet aggregation assay 
(HIPA), which also demonstrates the presence of a clinically relevant antibody. In the 
meantime, the medical team needs to initiate treatment based on the clinical symptoms and 
probability of a positive diagnosis of HIT (>6 points in scale proposed by Warkentin). 
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Fig. 1. 
4. Management 
Principles of treatment for patient diagnosed with HIT can be outlined in the following 
points. 
1. Discontinue all forms of heparin including line flushes, LMWH or lines coated with 
heparin (i.e. heparin-bound Swan-Ganz catheter). Even tiny amounts of heparin can 
precipitate HIT. 
2. Do not transfuse platelets to treat thrombocytopenia. Transfusion may precipitate 
further thrombotic events because HIT antibodies will activate transfused platelets.  
3. Initiate treatment with heparin alternatives, the most commonly used drugs belong to 2 
classes of anticoagulants: long acting, antithrombin III (ATIII) dependent factor Xa 
inhibiting oligosaccahrides or direct thrombin inhibitors (DTI). 
4. If patient is already receiving warfarin it should be reversed with vitamin K. During the 
early stages of warfarin therapy, levels of protein C (a natural anticoagulant) will drop 
before the rest of the coagulation factors are inhibited and this can make the patient 
even more pro-thrombotic at the initial stages of warfarin therapy.  
5. Warfarin therapy may be re-instituted when the platelets recover back to the baseline 
level. Warfarin derivatives must overlap for 4-5 days with anti Xa inhibitors or DTI 
therapy. 
It should be stressed that stopping heparin without initiating anti- Xa inhibitors or DTI 
therapy is not sufficient for prevention of thrombotic complications.  
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The fundamental difference between heparin and Xa inhibitors or DTIs lies in the 
mechanism of their action. Heparin requires a cofactor, which is called antithrombin- III 
(ATIII), additionally it can not bind to thrombin, which is already attached to a fibrin 
network. A long half-life and a stable level of anticoagulation characterize indirect factor Xa 
inhibitors, similar to heparin since they also require ATIII. The pharmacokinetic profile of 
anti-Xa inhibitors makes them favorable to use in the ICU setting (one dose a day). On the 
other hand, the fact that they do not have antidote may complicate clinical management in 
case patient requires surgical intervention. Specific assays are available to measure drug 
levels.  
The second group of medications DTIs bind and inhibit thrombin directly by connecting to 2 
active exosites. They have a short half-life and may interfere with the thrombin-induced 
protein C pathway. Similar to indirect Xa inhibitors, DTIs do not have an antidote, therefore 
their action cannot be reversed. All these agents can be safely used in patients with 
thrombocytopenia. 
Currently there are five main drugs used for HIT therapy: danaparoid, fondaparinux, 
bivalirudin, argatroban and hirudins. Danaparoid and fondaparinux belong to ATIII- 
dependent anti-Xa inhibitors, lepirudin, bavalirudin and argatroban belong to group of DTI. 
Danaparoid, lepirudin and argatroban are approved for treatment of HIT, bivalirudin and 
fondaparinux are not but have high rationale to be used for HIT therapy. Those five agents 
will be discussed below; additionally their brief characteristics are presented in Table 3.  
 
 
Non-thrombin Inhibitors 
 Danaparoid Ancrod 
T1/2 Elimination 7-25 hrs 3-5 hrs, >24 hr 
Monitoring Anti Xa levels Fibrinogen 
Reversal incomplete with protamine FFP, cryo 
Direct Thrombin Inhibitors 
 r-hirudin Argatroban Bivalirudin 
Thrombin binding Irreversible Reversible Reversible 
Metabolism Renal Hepatic Plasma, renal 
T1/2 Elimination 40-120 min 25-50 min 25 min 
Monitoring aPTT, ECT aPTT, ACT ECT, kACT 
Table 3. Short description of pharmacokinetic properties of alternative anticoagulants used 
in treatment of HIT 
Danaparoid. Danaparoid is a mixture of several glycoaminoglycans, mainly haparan sufate. 
It has both anti-thrombin and anti- Xa properties but later predominates. It can be given as 
subcutaneous or intravenous injection and has long half-life (25h). Danaparoid has a unique 
property; in therapeutic concentration it can inhibit platelet activation caused by HIT 
antibodies, stopping vicious circle of thrombotic complications. It is usually administered 
once a day and first dose should be given intravenously to rapidly achieve therapeutic 
concentration. Similar to other agents used for treatment of HIT Danaparoid has no 
antidote. 
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Fondaparinux. Fondaparinux also belongs to group of indirect anti-Xa inhibitors but when 
compared to Danaparoid it does not have anti-thrombin properties. Half-life of 
Fondaparinux is 17 h. Paradoxically, Fondaparinux can trigger formation of HIT antibodies 
but its use is still considered to be very effective treatment of HIT. 
R-Hirudins. Currently, there are two formulations of r-Hirudins available on the market: 
lepirudin and desirudin. Hirudins belong to DTI and have very high affinity to thrombin 
including molecules bonded to fibrin. This high affinity makes binding practically 
irreversible. Half-life of R-Hirudins is 80 min., they are eliminated almost exclusively by 
kidneys. In patients with kidney dysfunction half-life of r-Hirudins is totally unpredictable. 
R-hirudins are highly efficacious but treatment is complicated by high incidence of 
hemorrhagic complications (15%). Literature reports on several cases of lethal anaphylactic 
reactions complicating re-exposure to Hirudins.  
Argatroban. When compared to Hirudins, Argatroban bindings to thrombin are reversible. 
Drug is primarily metabolized and excreted by liver therefore is recommended for use in 
patients with kidney dysfunction or failure. Frequency of major bleeding complicating 
argatroban therapy is 8%, more over patients treated with Argatroban have high incidence 
of limb amputation. Most likely it is related to difficulties in achieving therapeutic level and 
fact that Argatroban artificially elevates values of INR. It may compromise safe overlap and 
transition from Argatroban therapy to Coumadin. Experience with Argatroban used for 
cardiac surgical procedures is highly unfavorable. 
Bivalirudin. Bivalirudin belongs to reversible DTI and among all agents used for HIT 
therapy presents most favorable pharmacokinetic profile. It has short half-life (25 min) and 
is primarily metabolized by plasma enzymatic degradation. It makes it drug of choice in 
patients with kidney and/or liver dysfunction (i.e. ICU patients). On the other hand due to 
plasma enzymatic degradation of bivalirudin any blood anticoagulated with this agent, 
which in stagnation will eventually clot. This property requires alternative approaches 
during CPB: the pump suckers must be replaced with cell saver and cardioplegia pump 
must be continuously flushed. Additionally, presence of clots in pericardium (stagnated 
blood) does not indicate that patient is not adequately anticoagulated. Therapy with 
Bivalirudin should be monitored with Ecarin Clotting Time (ECT), which is not available in 
many institutions. As an alternative one can use direct DTI assay or aPTT or plasma 
modified ACT if Bivalirudin is to be used for CPB purposes. Properties of Bivalirudin make 
it agent of choice for cardiac surgical procedures in HIT-positive patients who cannot be re-
scheduled beyond time when HIT antibodies disappear.  
5. HIT patient for CPB 
One of the most challenging situations facing cardiac anaesthesiologists is intra-operative 
management of the patient who requires a cardiac surgical procedure who is HIT positive. 
Whenever possible it is recommended to delay surgery until the HIT antibodies have 
cleared (on average 100 days). Unfortunately, in some clinical situations it is not possible; for 
example: left main stenoses with symptoms of unstable angina, rapidly progressing 
endocarditis or heart transplantation are among the most common clinical scenarios. Among 
all of the presented agents (see Table 3), none of them is approved for anticoagulation 
during cardiopulmonary bypass (CPB). Therefore therapy with DTIs or indirect anti Xa 
inhibitors during cardiac surgery with use of CPB should be considered as an “off-label” 
application for these drugs. All of them have been used in different doses with varying 
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protocols and outcomes were not always favorable. Their recommended doses and 
protocols for clinical use are presented in Table 4. When comparing all of these agents, 
Bivalirudin appears to offer that most favorable outcome with respect to control of 
anticoagulation during extracorporeal circulation. The features of Bivalirudin, which makes 
it a favorable agent for use with CPB are: a short half-life and metabolism that is 
independent from kidney and liver function. A protocol based on data from the literature 
and our own experience is presented in the Appendix 1. 
 
 
Anticoagulant Dosages for CPB 
Danaparoid Bolus 125 units kg-1 iv, post thoracotomy 
CPB prime 3 units ml-1   
Infusion 7 units kg-1 h-1 iv on CPB  
If clotting noted additional bolus 1250 units 
Stop infusion 45 minutes before end of CPB 
Ancrod Infusion 8.4 units h-1 x 12hrs preoperatively check fibrinogen 
levels q 4hrs  
Stop infusion preoperatively once the target fibrinogen level of 
0.4-0.8 gm L-1 is reached  
If fibrinogen > 0.8 gm L-1 restart the infusion at 2.1 units h-1  
Hirudin Bolus 0.25 mg kg-1, pre cannulation 
CPB prime 0.25 mg kg-1  
Infusion 0.5 mg min-1 iv, maintain ECT > 400s  
Additional bolus to maintain ECT 
Stop infusion before end of  CPB 
Argatroban Bolus 0.1 mg kg-1 iv, 20 minutes pre cannulation 
Infusion 5-10 ug kg-1 min-1 iv, maintain ACT > 400s  
CPB prime 0.05 mg kg-1  
Additional 2 mg iv boluses to maintain ACT  
Stop infusion before end of CPB 
Bivalirudin Bolus 1.5 mg kg-1 iv, pre cannulation 
CPB prime 50mg 
Infusion 2.5 mg kg-1 h-1 iv, maintain ECT > 400s 
Stop infusion before end of CPB 
Table 4. Dosages of alternative anticoagulants used for patients who are HIT positive and 
require cardiac surgery with the use of cardiopulmonary bypass  
It should be mentioned that there are some reports in the literature recommending the use 
of strategies other than using a DTI or indirect Xa inhibitor for anticoagulation during CPB. 
The most encouraging of those are: use of plasmapheresis prior to CPB to clear all HIT 
antibodies followed by use of regular doses of heparin or to use a prostacyclin infusion 
combined with antiplatelet therapy with GPIIb/GPIIIa inhibitors.  
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Appendix 1 Scheme of CPB approach with bivalirudin anticoagulation for HIT 
positive patients 
Requirements For Anesthesiologist For Surgeon For Perfusionists 
Staffing 2 anesthesiologist 
required, one responsible 
for anticoagulation, one 
for anesthesia  
Regular setup  2 perfusionists required 
Anticoagulation Separate line for 
bivalirudin 
Bolus 1-1.5 mg/kg 
Followed by infusion 
2.5mg/kg/h 
Discontinue infusion 15 
min. prior to 
decannulation 
Stagnant blood will 
clot (pericardium, 
pleura)-do not 
panic 
Suction-only from 
cell saver 
Consider 
continuous 
cardioplegia 
Consider flushing 
grafts with 
bivalirudin 
solution (0.1 
mg/ml) 
50 mg of bivalirudin into 
pump prime 
Monitor anticoagulation 
with Ecarin Clotting time 
(>400 sec) or ACT> 370 sec 
Additional bolus of 
0.25mg/kg if ECT/ACT 
values below 
recommended, consider 
increasing infusion after 
bolus 
Cannot use suction units 
of CPB machine- only cell 
saver 
Have second circuit as a 
back-up solution 
Hemostasis Maintain normothermia 
after CPB 
Maximum dose of 
antifibrinolitic 
Be prepared for massive 
transfusion protocol 
No antidote for 
bivalirudin 
Meticulous 
haemostasis 
Bleeding might 
continue for up to 
45 min. after 
commencing CPB 
 
Cell saver use to continue 
after CPB 
Be prepared to perform 
ultrafiltration after CPB to 
speed up elimination of 
bivalirudin. 
Extra pump blood must be 
stored in citrated bags 
Other important 
points 
Reduce doses in patients 
with kidney dysfunction 
Flush you 
mammary every 10 
min 
Divede duties between 2 
perfusionists prior to 
procedure 
Equipment Everything heparin free 
(lines, line flushed, PA 
catheters)  
Lots of additional 
equipment in the 
room 
Cell saver, additional 
pump as backup, ECT 
machine if available in 
your institution 
Appendix 1. 
6. Summary 
HIT represents a rare but potentially life threatening complication of heparin therapy. Its 
pathogenesis is based on an immunological reaction specifically the formation of antibodies 
directed against a complex of heparin and PF-4. Secondary exposure to heparin triggers a 
reaction leading to activation of platelets, their aggregation and adhesion to endothelium 
leading to formation of clots (80% in the venous system and 20% in arteries) and subsequent 
thrombotic events. 
The definitive diagnosis of HIT requires sophisticated laboratory tests that may take a while 
to get results from. Therefore treatment should be initiated before final results are obtained 
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based on high clinical suspicion. The most important principles of therapy include: 
discontinuation of any form of heparin therapy, treatment with indirect inhibitors of factor 
Xa or direct thrombin inhibitors and reversal of vitamin K antagonists if they were used 
previously. Additionally, transfusion of platelets should be avoided since it will only 
precipitate their activation and aggravate the clinical symptoms. 
7. Key points 
 Heparin -induced thrombocytopenia (HIT) is a rare highly under-diagnosed but life 
threatening complication of heparin therapy.  
 HIT is a clinico-pathological syndrome requiring multiple laboratory tests to make the 
final diagnosis. Most often treatment must be initiated before final diagnosis is 
established  
 The most important principles of therapy include: discontinuation of any form of 
heparin, avoidance of platelet transfusion, treatment with indirect inhibitors of factor 
Xa or direct thrombin inhibitors and reversal of vitamin K antagonists if they were used 
previously. 
 Management of a HIT-positive patient undergoing cardiac surgery with the use of CPB 
presents a challenge for the anesthesiologist. 
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